Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34475539 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL1828890 | 0.97 | — | — | |
| SCHEMBL21573995 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| Hydrochloric Acid SCHEMBL23123281 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL16877500 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25231616 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL20104746 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL25229684 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 | |
| SCHEMBL1286818 | 0.97 | — | — | |
| SCHEMBL1829729 | 0.97 | CHEK1 (0.35) | CHEK1AURKARPS6KA5CHEK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-03-28 | — | — | US | claimed |
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | claimed |
| EP-4298095-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | Sperogenix Therapeutics Limited (HK) | 2024-01-03 | — | — | EP | claimed |
| WO-2023159322-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-08-31 | — | — | WO | claimed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | claimed |
| WO-2022162606-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LIMITED (CN) | 2022-08-04 | — | — | WO | claimed |
| JP-9110835-A | — | — | None | — | — | JP | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| CN-120004902-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119930630-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925375-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-115151535-B | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2003024451-A1 | 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-6506764-B1 | B-X-(CH2)m-CR1R2-(CH2)n-CO-Y (I) have therapeutic utility as inhibitors of metalloproteinases etc. for medicine by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with | DARWIN DISCOVERY, LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-1177174-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000069822-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
| JP-H09110835-A | 6-AZASPIRO(4,5)DECANE DERIVATIVE | SAGAMI CHEM RES CENTER | 1997-04-28 | — | — | JP | disclosed |
| WO-1996011927-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0128120-A2 | Trisubstituted oxazolidinones | CIBA-GEIGY AG (CH) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | CHEK1 34/4885AURKA 60/4885RPS6KA5 209/4885 |
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LANCL2, CBS, LCP2 | CHEK1 4009/4885AURKA 4753/4885RPS6KA5 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.